These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1499007)

  • 1. Genetic factors in the metabolism of haloperidol.
    Llerena A; Dahl ML; Ekqvist B; Bertilsson L
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():84A-85A. PubMed ID: 1499007
    [No Abstract]   [Full Text] [Related]  

  • 2. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
    Llerena A; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Jun; 14(3):261-4. PubMed ID: 1412613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
    Llerena A; Alm C; Dahl ML; Ekqvist B; Bertilsson L
    Ther Drug Monit; 1992 Apr; 14(2):92-7. PubMed ID: 1585408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haloperidol determination in serum and cerebrospinal fluid using gas--liquid chromatography with nitrogen--phosphorus detection: application to pharmacokinetic studies.
    Abernethy DR; Greenblatt DJ; Ochs HR; Willis CR; Miller DD; Shader RI
    J Chromatogr; 1984 Apr; 307(1):194-9. PubMed ID: 6725485
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
    Spina E; Steiner E; Ericsson O; Sjöqvist F
    Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.
    Llerena A; Cobaleda J; Martínez C; Benítez J
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):129-38. PubMed ID: 8839686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual variability in response to haloperidol.
    Forsman AO
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):9-12. PubMed ID: 1019146
    [No Abstract]   [Full Text] [Related]  

  • 8. The debrisoquin hydroxylation phenotype does not predict the metabolism of phenytoin.
    Steiner E; Alván G; Garle M; Maguire JH; Lind M; Nilson SO; Tomson T; McClanahan JS; Sjöqvist F
    Clin Pharmacol Ther; 1987 Sep; 42(3):326-33. PubMed ID: 3621788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A gas chromatographic method for determining haloperidol. A sensitive procedure for studying serum concentration and pharmacokinetics of haloperidol in patients.
    Forsman A; Mårtensson E; Nyberg G; Ohman R
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 286(2):113-24. PubMed ID: 4281877
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of haloperidol and hydroxy haloperidol in human plasma by high performance liquid chromatography.
    Pommery J; Foulon O; Morineau G; Lhermitte M; Levron JC; Erb F
    Ann Biol Clin (Paris); 1990; 48(7):455-8. PubMed ID: 2278409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between uptake and elimination of toluene and debrisoquin hydroxylation polymorphism.
    Löf A; Hansen SH; Näslund P; Steiner E; Wallén M; Hjelm EW
    Clin Pharmacol Ther; 1990 Mar; 47(3):412-7. PubMed ID: 2311341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol.
    Chang WH; Lam YW; Jann MW; Chen H
    Psychopharmacology (Berl); 1992; 106(4):517-22. PubMed ID: 1579624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia.
    Eyles DW; McLennan HR; Jones A; McGrath JJ; Stedman TJ; Pond SM
    Clin Pharmacol Ther; 1994 Nov; 56(5):512-20. PubMed ID: 7955815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interconversion between haloperidol and reduced haloperidol in healthy volunteers.
    Chakraborty BS; Hubbard JW; Hawes EM; McKay G; Cooper JK; Gurnsey T; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1989; 37(1):45-8. PubMed ID: 2591462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol.
    Yasui N; Otani K; Kondo T; Suzuki A; Furukori H; Kaneko S; Inoue Y
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Apr; 22(3):485-92. PubMed ID: 9612845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydrolysis of haloperidol decanoate in vitro by cultured cells.
    Oh-e Y; Miyazaki H; Matsunaga Y; Nambu K; Kobayashi N; Hashimoto M
    Eur J Drug Metab Pharmacokinet; 1987; 12(3):183-8. PubMed ID: 3436340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro metabolism of haloperidol and sila-haloperidol: new metabolic pathways resulting from carbon/silicon exchange.
    Johansson T; Weidolf L; Popp F; Tacke R; Jurva U
    Drug Metab Dispos; 2010 Jan; 38(1):73-83. PubMed ID: 19812350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol half-life after chronic dosing.
    de Leon J; Diaz FJ; Wedlund P; Josiassen RC; Cooper TB; Simpson GM
    J Clin Psychopharmacol; 2004 Dec; 24(6):656-60. PubMed ID: 15538130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.